# Dr Reddys Laboratories Ltd (RDY)

Source page: https://stoqly.net/companies/rdy

- **Ticker:** RDY (NYSE)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001135951
- **Latest annual report:** 20-F filed 2026-05-29 (https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $14.17 on 2026-10-30
- **Market cap:** $11.8B
- **P/E (trailing):** 24.4x
- **EPS, trailing 12 months:** $0.58
- **Revenue (FY2026):** $3.8B
- **Revenue growth:** −1.3%
- **Revenue growth, 5-year CAGR:** +8.3%
- **Gross margin:** 52.8%
- **Operating margin:** 15.0%
- **Net margin:** 12.8%
- **Free cash flow:** $378M
- **Free cash flow margin:** 10.0%
- **Return on invested capital:** 10.9%
- **Return on equity:** 12.2%
- **Net debt:** $30.2M
- **Net debt / EBITDA:** 0.0x
- **Change in share count:** −0.1%
- **Piotroski F-score:** 4/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/rdy/figures.csv

| US$ millions | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 2,100 | 2,203 | 2,200 | 2,462 | 2,556 | 2,877 | 3,060 | 3,372 | 3,850 | 3,801 |
| Operating income | 201 | 185 | 299 | 226 | 327 | 396 | 711 | 818 | 850 | 572 |
| Net income | 180 | 152 | 269 | 275 | 232 | 316 | 561 | 673 | 669 | 485 |
| Diluted EPS (US$) | 1.08 | 0.92 | 1.62 | 1.66 | 1.40 | 1.90 | 0.67 | 0.81 | 0.80 | 0.58 |
| Operating cash flow | 321 | 280 | 410 | 421 | 481 | 377 | 733 | 549 | 549 | 642 |
| Free cash flow | 138 | 136 | 311 | 352 | 350 | 180 | 592 | 351 | 224 | 378 |
| Cash | 60 | 40 | 32 | 27 | 203 | 196 | 70 | 85 | 172 | 164 |
| Debt and leases | 86 | 388 | 381 | 74 | 98 | 89 | 74 | 88 | 102 | 194 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.